{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:49:29Z","timestamp":1792532969820,"version":"4.5.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The relationship between immune-related thyroid dysfunction (irTD) and survival rates in cancer patients remains unclear. Furthermore, the impact of variations in immunotherapy line numbers and pathological types among lung cancer patients on this relationship has not been fully elucidated. This study aims to evaluate the potential of irTD as a prognostic marker for immunotherapy in Chinese patients with lung cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective analysis was conducted on data collected from patients with locally advanced or metastatic lung cancer who received immune checkpoint inhibitor treatment at the Harbin Medical University Cancer Hospital. The study period spanned from December 1, 2016, to November 30, 2023. The primary endpoints were progression-free survival (PFS) and overall survival (OS), while the objective response rate served as the secondary endpoint.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 361 patients in this study, 42.7% developed irTD. Significant differences were observed between the groups with and without irTD regarding inflammatory indices, thyroid-stimulating hormone levels, and thyroid autoantibody positivity (P &amp;lt; 0.05). Patients with irTD demonstrated longer OS (32.5 vs. 22 months, HR: 0.65, 95% CI: 0.49-0.88; P = 0.005). For NSCLC patients, OS was significantly prolonged in those with irTD (40.8 vs. 27.2 months, HR: 0.68, 95% CI: 0.48-0.96; P = 0.028). Similarly, SCLC patients who developed irTD exhibited longer OS (27.9 vs. 13.8 months, HR: 0.51, 95% CI: 0.29-0.90; P = 0.022). Notably, irTD was observed exclusively in patients receiving immunotherapy in the second or later lines, showing a significant association with extended OS (40.8 vs. 19.4 months, HR: 0.56, 95% CI: 0.35-0.88; P = 0.012), while the presence of irTD during first-line immunotherapy did not confer a benefit to patients (32.4 vs 24.5 months, HR: 0.74, 95% CI: 0.50-1.10; P = 0.134). The effects of different irTD types, severities, or clinical symptoms on PFS and OS did not differ significantly (P &amp;gt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>irTD demonstrates potential as a predictive marker for long-term survival benefits in Chinese patients with lung cancer. However, our exploratory analysis indicates that this association was exclusively observed in individuals receiving immunotherapy as a second-line or subsequent treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1495460","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T06:39:15Z","timestamp":1734935955000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Immune-related thyroid dysfunction as a positive prognostic factor for patients with lung cancer in China: a real-world retrospective study"],"prefix":"10.3389","volume":"15","author":[{"given":"Ge","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenrui","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JunJie","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruqiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun Signal"},{"key":"B2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/cells11030320","article-title":"Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects","volume":"11","author":"Tang","year":"2022","journal-title":"Cells."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2174\/0929867329666220819115849","article-title":"Immune checkpoint inhibitors: recent clinical advances and future prospects","volume":"30","author":"Banday","year":"2023","journal-title":"Curr Med Chem"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.649863","article-title":"Immune checkpoint inhibitors-related thyroid dysfunction: epidemiology, clinical presentation, possible pathogenesis, and management","volume":"12","author":"Zhan","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12020-024-03718-2","article-title":"S.A. Paschou, Thyroid disorders induced by immune checkpoint inhibitors","volume":"85","author":"Karaviti","year":"2024","journal-title":"Endocrine."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw640","article-title":"M.D. Hellmann, Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03323-9","article-title":"Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study","volume":"81","author":"Wu","year":"2023","journal-title":"Endocrine."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e1375642","DOI":"10.1080\/2162402x.2017.1375642","article-title":"Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer","volume":"7","author":"Kim","year":"2017","journal-title":"Oncoimmunology."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab263","article-title":"A.M. Menzies, thyroid immune-related adverse events following immune checkpoint inhibitor treatment","volume":"106","author":"Muir","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01082-5","article-title":"Immune-related thyroid dysfunctions during anti PD-1\/PD-L1 inhibitors: new evidence from a single centre experience","volume":"23","author":"Nervo","year":"2023","journal-title":"Clin Exp Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-23-1092","article-title":"Immune-related thyroid dysfunction in patients with non-small cell lung cancer","volume":"16","author":"Cai","year":"2024","journal-title":"J Thorac Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.627089","article-title":"Fatal adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis","volume":"8","author":"Yu","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.90a.22032","article-title":"Endocrinopathies from checkpoint inhibitors: Incidence, outcomes, and management","volume":"90","author":"Kennedy","year":"2023","journal-title":"Cleve Clin J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03151-2","article-title":"D.E. Gerber, Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors","volume":"71","author":"von Itzstein","year":"2022","journal-title":"Cancer Immunol Immunother."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2019.1709344","article-title":"Immune checkpoint inhibitors and endocrine side effects, a narrative review","volume":"132","author":"Agrawal","year":"2020","journal-title":"Postgrad Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","author":"Delivanis","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27077","article-title":"Thyroid dysfunction (TD) induced by PD-1\/PD-L1 inhibitors in advanced lung cancer","volume":"10","author":"Wang","year":"2024","journal-title":"Heliyon."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102590","article-title":"Immune checkpoint inhibitors-induced autoimmunity: The impact of gender","volume":"19","author":"Triggianese","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e3620","DOI":"10.1210\/clinem\/dgaa458","article-title":"Immune checkpoint inhibitor-induced thyroid dysfunction is associated with higher body mass index","volume":"105","author":"Pollack","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyab043","article-title":"Immune checkpoint inhibitor-related new-onset thyroid dysfunction: A retrospective analysis using the US FDA adverse event reporting system","volume":"27","author":"Lu","year":"2022","journal-title":"Oncologist."},{"key":"B23","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system","volume":"7","author":"Zhai","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14363","article-title":"Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors","volume":"111","author":"Kurimoto","year":"2020","journal-title":"Cancer Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12902-022-01004-8","article-title":"Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients","volume":"22","author":"Baek","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107296","article-title":"Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer","volume":"91","author":"Zhou","year":"2021","journal-title":"Int Immunopharmacol."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01508-5","article-title":"Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy","volume":"44","author":"Luongo","year":"2021","journal-title":"J Endocrinol Invest."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03128-7","article-title":"Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"71","author":"Cheung","year":"2022","journal-title":"Cancer Immunol Immunother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"690","DOI":"10.21037\/jtd-23-254","article-title":"Immune-related thyroid dysfunction is associated with improved long-term prognosis in patients with non-small cell lung cancer treated with immunotherapy: a systematic review and meta-analysis","volume":"15","author":"Li","year":"2023","journal-title":"J Thorac Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1402017","article-title":"Association between immune-related adverse events and prognosis in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"14","author":"Ma","year":"2024","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12931-024-02885-0","article-title":"Tumor mutational burden adjusted by neutrophil-to-lymphocyte ratio serves as a potential biomarker for atezolizumab-treated patients with extensive stage small cell lung cancer","volume":"25","author":"Zhang","year":"2024","journal-title":"Respir Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6645","article-title":"H.M. Lazarus, Real-world outcomes of 18,186 metastatic solid tumor outpatients: Baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapy","volume":"12","author":"Goldschmidt","year":"2023","journal-title":"Cancer Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e0216954","DOI":"10.1371\/journal.pone.0216954","article-title":"Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab","volume":"14","author":"Yamauchi","year":"2019","journal-title":"PloS One"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2022.101660","article-title":"Immune checkpoint inhibitor-related thyroid dysfunction","volume":"36","author":"Iwama","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12931-024-02890-3","article-title":"Correlation between immune-related adverse events and efficacy of PD-(L)1 inhibitors in small cell lung cancer: a multi-center retrospective study","volume":"25","author":"Zhang","year":"2024","journal-title":"Respir Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-23-754","article-title":"Aurora kinase B inhibition in small-cell lung cancer: BCL-2 as a potential therapeutic biomarker and combination target","volume":"13","author":"Hosoya","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113581","article-title":"Recent advances and future strategies in first-line treatment of ES-SCLC","volume":"200","author":"Gomez-Randulfe","year":"2024","journal-title":"Eur J Cancer."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21785","article-title":"Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions","volume":"73","author":"Megyesfalvi","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2146-8","article-title":"Cancer immunotherapy in patients with brain metastases","volume":"67","author":"Caponnetto","year":"2018","journal-title":"Cancer Immunol Immunother."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2023.100596","article-title":"Multi-omics indicators of long-term survival benefits after immune checkpoint inhibitor therapy","volume":"3","author":"Zhao","year":"2023","journal-title":"Cell Rep Methods"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107418","article-title":"Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide","volume":"186","author":"Liu","year":"2023","journal-title":"Lung Cancer."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1495460\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T06:39:17Z","timestamp":1734935957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1495460\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2024.1495460"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1495460","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"article-number":"1495460"}}